Naprolen is used to treat pain and inflammation in such conditions as arthritis, tendinitis, bursitis, ankylosing spondylitis, gout or menstrual cramps.
The nosological classification (ICD-10) of Naprelan
J06 Acute upper respiratory infections of multiple and unspecified
K08.8.0 * Pain tooth
M06.9 Rheumatoid arthritis, unspecified
M08.0 Juvenile rheumatoid arthritis
M10.0 Idiopathic gout
M19.9 Arthritis, unspecified
M45 Ankylosing spondylitis
Unspecified M77.9 Enthesopathy
M79.2 Neuralgia and neuritis, unspecified
M89.9 bone disease, unspecified
And oophoritis N70 Salpingitis
N94.4 Primary dysmenorrhoea
R50 Fever of unknown origin
Unspecified R52.9 Pain
T14.9 Injury, unspecified
Z100 * CLASS XXII Surgical practice
Pharmacology of Naprelan
Mode of action – anti-inflammatory, analgesic, antipyretic, antiagregatine.
Indications for use of Naprelan
Inflammatory and degenerative diseases of the musculoskeletal system, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome in exacerbation of gout, juvenile rheumatoid arthritis; pain: neuralgia, myalgia, ossalgia, sciatica, headache and tooth pain, tendonitis, pain in cancer, postoperative pain, accompanied by inflammation, trauma of the musculoskeletal system and soft tissue, adnexitis, primary dysmenorrhea; pain and fever in infectious and inflammatory diseases of the upper respiratory tract (in the complex therapy).
Contraindications of Naprelan
Hypersensitivity, aspirin asthma, “Aspirin” triad (a combination of asthma, recurrent nasal polyposis, and paranasal sinuses and intolerance of aspirin and drugs pirazolonovogo series), erosive and ulcerative lesions of the gastrointestinal tract in the acute phase of the breach of blood, liver and / or kidney failure, children up to 1 year.
Before using the medication please consult with your doctor to avoid overdose Naprelan and not cause a complication of the disease.
Side effects of Naprelan
The side effects most commonly encountered in clinical trials (possibly associated with the use of naproxen)
From the digestive tract: 3-9% – heartburn, abdominal pain, nausea, constipation; > 1% – diarrhea, dyspepsia, stomatitis; <1% – bloating, bleeding / perforation, gastrointestinal ulcer (gastroduodenal), vomiting, increase in liver transaminases. From the nervous system and sensory organs: 3-9% – headache, drowsiness, dizziness, tinnitus, visual impairment, hearing impairment; > 1% – vertigo.
Cardio-vascular system and blood (blood, hemostasis):> 1% – heart rate; <1% – anemia, increased bleeding time.
From the respiratory system: 3-9% – dyspnea.
For the skin: 3-9% – ecchymosis.
With the genitourinary system: <1% – renal dysfunction. Allergic reactions: 3-9% – itching, skin rash, anaphylactoid reaction. Other: 3-9% – edema; > 1% – increased sweating, purpura, thirst.
Adverse events occurred at a frequency <1% in clinical trials and post-marketing studies (possibly associated with the use of naproxen)
From the digestive tract: colitis, hematemesis, jaundice, pancreatitis, melena.
With the genitourinary system: glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal failure, renal papillary necrosis.
Cardio-vascular system and blood (blood, hemostasis): agranulocytosis, eosinophilia, granulocytopenia, leukopenia, thrombocytopenia.
From the nervous system and sensory organs, depression, abnormal dreams, inability to concentrate, insomnia, malaise, myalgia, muscle weakness.
Adverse events occurred at a frequency <1% (causal relationship to the use of naproxen is not installed):
Cardio-vascular system and blood (blood, hemostasis): aplastic anemia, hemolytic anemia.
From the nervous system and sensory organs: aseptic meningitis, cognitive dysfunction.
From the digestive tract: ulceration gastrointestinal tract, ulcerative stomatitis.
Allergic reactions: epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome, urticaria; photosensitivity reaction.
Others: Vasculitis, hyper / hypoglycemia, alopecia, foto dermatitis.